This invention discloses the application of KL-6, alone and in combination with other immune inflammatory markers, in the identification of complex
silicosis and the assessment of pulmonary function impairment. First, the application of KL-6 in the preparation of products for the identification of complex
silicosis and the assessment of pulmonary function impairment is disclosed. Further, the application of KL-6 in combination with other immune inflammatory markers in the preparation of products for the identification of complex
silicosis and the assessment of pulmonary function impairment is disclosed. This invention uses KL-6 as the core, combined with LDH and ESR to construct a diagnostic scheme that can distinguish complex silicosis from dust
exposure or simple silicosis; simultaneously, KL-6 shows a significant
negative correlation with pulmonary function parameters, which can help assess the severity of the
disease and the extent of pulmonary function impairment. This invention provides rapid and accurate diagnosis, is easy to operate, cost-effective, and allows for batch testing, making it suitable for health monitoring of high-risk occupational groups and providing efficient
technical support for the early identification of complex silicosis, the assessment of pulmonary function impairment, and
clinical decision-making.